Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH; IC50 value 134 nM for human DHODH mediated DCIP reduction) and lymphocyte proliferation in vitro. Vidofludimus inhibits the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with Phytohemagglutinin-L, and interleukin (IL)-17 secretion from human peripheral blood mononuclear cells in a dose-related fashion (IC50 of 6 µM approx.) and independently of lymphocyte proliferation. May be applied for treatment of rheumatoid arthritis and inflammatory bowel disease, and as immunosuppressant after renal transplantation.